Cannabinoids augment the release of neuropeptide Y in the rat hypothalamus - PubMed (original) (raw)
Cannabinoids augment the release of neuropeptide Y in the rat hypothalamus
Kevin M Gamber et al. Neuropharmacology. 2005 Oct.
Abstract
Little is known about the mechanism of action behind the orexigenic activity of cannabinoids. Neuropeptide Y (NPY) is one of the most potent orexigenic factors and is a key mediator in the hypothalamic control of food intake. We examined the effect of cannabinoids on NPY release using a rat hypothalamic explant model. The cannabinoid agonists anandamide (AEA) and CP55,940 both significantly augmented resting and KCl-evoked NPY release. AM251, a cannabinoid receptor antagonist, blocked the augmentation of NPY release elicited by AEA and CP55,940. Additionally, AM251 administered alone, in the absence of exogenous cannabinoid agonists, inhibited NPY release demonstrating the role of endogenous cannabinoids in NPY release. Combined, these findings demonstrate that cannabinoids augment NPY release in the hypothalamus and that this may be a potential mechanism behind the orexigenic activity of cannabinoids.
Similar articles
- Dynorphin B and spinal analgesia: induction of antinociception by the cannabinoids CP55,940, Delta(9)-THC and anandamide.
Houser SJ, Eads M, Embrey JP, Welch SP. Houser SJ, et al. Brain Res. 2000 Feb 28;857(1-2):337-42. doi: 10.1016/s0006-8993(00)01981-8. Brain Res. 2000. PMID: 10700588 - A synthetic cannabinoid, CP55940, inhibits lipopolysaccharide-induced cytokine mRNA expression in a cannabinoid receptor-independent mechanism in rat cerebellar granule cells.
Chiba T, Ueno S, Obara Y, Nakahata N. Chiba T, et al. J Pharm Pharmacol. 2011 May;63(5):636-47. doi: 10.1111/j.2042-7158.2011.01250.x. Epub 2011 Mar 28. J Pharm Pharmacol. 2011. PMID: 21492165 - Role of CB1 and CB2 receptors in the inhibitory effects of cannabinoids on lipopolysaccharide-induced nitric oxide release in astrocyte cultures.
Molina-Holgado F, Molina-Holgado E, Guaza C, Rothwell NJ. Molina-Holgado F, et al. J Neurosci Res. 2002 Mar 15;67(6):829-36. doi: 10.1002/jnr.10165. J Neurosci Res. 2002. PMID: 11891798 - The role of endocannabinoids in the hypothalamic regulation of visceral function.
Wenger T, Moldrich G. Wenger T, et al. Prostaglandins Leukot Essent Fatty Acids. 2002 Feb-Mar;66(2-3):301-7. doi: 10.1054/plef.2001.0353. Prostaglandins Leukot Essent Fatty Acids. 2002. PMID: 12052044 Review. - Effects of cannabinoids on hypothalamic and reproductive function.
Maccarrone M, Wenger T. Maccarrone M, et al. Handb Exp Pharmacol. 2005;(168):555-71. doi: 10.1007/3-540-26573-2_18. Handb Exp Pharmacol. 2005. PMID: 16596787 Review.
Cited by
- Hypothalamic cannabinoid signaling: Consequences for eating behavior.
Lord MN, Noble EE. Lord MN, et al. Pharmacol Res Perspect. 2024 Oct;12(5):e1251. doi: 10.1002/prp2.1251. Pharmacol Res Perspect. 2024. PMID: 39155548 Free PMC article. Review. - Dietary PUFAs and Exercise Dynamic Actions on Endocannabinoids in Brain: Consequences for Neural Plasticity and Neuroinflammation.
Park Y, Watkins BA. Park Y, et al. Adv Nutr. 2022 Oct 2;13(5):1989-2001. doi: 10.1093/advances/nmac064. Adv Nutr. 2022. PMID: 35675221 Free PMC article. Review. - Involvement of the cannabinoid system in chronic inflammatory intestinal diseases: opportunities for new therapies.
Lima PA, Berg BB, Castor MGME. Lima PA, et al. Intest Res. 2022 Oct;20(4):392-417. doi: 10.5217/ir.2021.00160. Epub 2022 May 31. Intest Res. 2022. PMID: 35645322 Free PMC article. Review. - Orchestration of the circadian clock and its association with Alzheimer's disease: Role of endocannabinoid signaling.
Kumar D, Sharma A, Taliyan R, Urmera MT, Herrera-Calderon O, Heinbockel T, Rahman S, Goyal R. Kumar D, et al. Ageing Res Rev. 2022 Jan;73:101533. doi: 10.1016/j.arr.2021.101533. Epub 2021 Nov 26. Ageing Res Rev. 2022. PMID: 34844016 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous